Randomized crossover pharmacokinetic evaluation of subcutaneous versus intravenous granisetron in cancer patients treated with platinum-based chemotherapy
Alfonso Gurpide (a), Belen Sádaba (b), Salvador Martín-Algarra (a), José R. Azanza (b), José M. Lopez-Picazo (a), Miguel A. Campanero (b), Juan P. Cabello (a), Isabel Gil-Aldea (b), Susana de la Cruz (a), Victor Fernández Gallego (b), Carmen Reyna (b), Clara Olier Garate (a), A J. Blanco-Prieto (b), Jaime Ceballos (a), Jesús García-Foncillas (a), Jose L Pérez-Gracia (a)
(a) Oncology Department and (b) Clinical Pharmacology Department, Clinica Universitaria de Navarra, University of Navarra, Navarra, Spain
Data: 1/Set/2007Farmacologia Clínica [ES] Unidade de Investigação Clínica [ES] Oncologia Médica
5-HT3-receptor antagonists are one of the mainstays of antiemetic treatment, and they are administered either i.v. or orally. Nevertheless, sometimes neither administration route is feasible, such as in patients unable to admit oral intake managed in an outpatient setting. Our objective was to evaluate the bioavailability of s.c. granisetron.
PATIENTS AND METHODS
Patients receiving platinum-based chemotherapy were randomized to receive 3 mg of granisetron either s.c. or i.v. in a crossover manner during two cycles. Blood and urine samples were collected after each cycle. Pharmacokinetic parameters observed with each administration route were compared by analysis of variance.
From May to November 2005, 31 patients were included and 25 were evaluable. Subcutaneous granisetron resulted in a 27% higher area under the concentration-time curve for 0-12 hours (AUC(0-12h)) and higher levels at 12 hours, with similar values for AUC(0-24h). The maximum concentration was lower with the s.c. than with the i.v. route and was observed 30 minutes following s.c. administration.
Granisetron administered s.c. achieves complete bioavailability. This is the first study that shows that s.c. granisetron might be a valid alternative to i.v. delivery. Further trials to confirm clinical equivalence are warranted. This new route of administration might be especially relevant for outpatient management of emesis in cancer patients.
CITAÇÃO DO ARTIGO Oncologist. 2007 Sep;12(9):1151-5
A Clínica é o hospital privado com maiores recursos tecnológicos de Espanha, tudo num único centro.
Os profissionais da Clínica realizam um trabalho contínuo de investigação e formação, sempre em benefício do paciente.
Conheça porque é que somos diferentes em relação a outros centros sanitários. Qualidade, rapidez, comodidade e resultados.